Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
ACS Chem Neurosci ; 13(23): 3303-3313, 2022 12 07.
Article in English | MEDLINE | ID: mdl-36347018

ABSTRACT

A tetrahydroisoquinoline identified in Mucuna pruriens ((1R,3S)-6,7-dihydroxy-1-methyl-1,2,3,4-tetrahydroisoquinoline-1,3-dicarboxylic acid, compound 4) was synthesized and assessed for its in vitro pharmacological profile and in vivo effects in two animal models of Parkinson's disease. Compound 4 inhibits catechol-O-methyltransferase (COMT) with no affinity for the dopaminergic receptors or the dopamine transporter. It restores dopamine-mediated motor behavior when it is co-administered with L-DOPA to C. elegans worms with 1-methyl-4-phenylpyridinium-damaged dopaminergic neurons. In a 6-hydroxydopamine rat model of Parkinson's disease, its co-administration at 30 mg/kg with L-DOPA enhances the effect of L-DOPA with an intensity similar to that of tolcapone 1 at 30 mg/kg but for a shorter duration. The effect is not dose-dependent. Compound 4 seems not to cross the blood-brain barrier and thus acts as a peripheral COMT inhibitor. COMT inhibition by compound 4 further validates the traditional use of M. pruriens for the treatment of Parkinson's disease, and compound 4 can thus be considered as a promising drug candidate for the development of safe, peripheral COMT inhibitors.


Subject(s)
Levodopa , Parkinson Disease , Animals , Rats , Levodopa/pharmacology , Levodopa/therapeutic use , Parkinson Disease/drug therapy , Catechol O-Methyltransferase , Caenorhabditis elegans , Personality
2.
J Pharm Biomed Anal ; 212: 114598, 2022 Apr 01.
Article in English | MEDLINE | ID: mdl-35152005

ABSTRACT

Pharmacological treatment of Parkinson's disease consists of a combined chemotherapy that mostly relies on levodopa (L-DOPA) administration together with inhibitors of dopa-decarboxylase (DDC), monoamine oxidase (MAO) and catechol-methyltransferase (COMT). Identification of inhibitors specifically targeting these enzymes is still a significative part of the development of new alternative antiparkinsonian drugs. Most of the available methods use measurement of enzymatic reactions through radioactive labeling, antibody-recognized products or coupled enzymatic assays. Mass spectrometry (MS) represents an interesting alternative approach as it allows direct and specific detection and quantification of enzymatic reactions. We describe the development of a simple, reliable, label-free assay based on high-resolution mass spectrometry (HRMS) for the detection and relative quantification of three different enzymatic reactions using non-isolated enzymes. The assay was applied both to reference drugs and plant crude extracts. This method can be used to detect hits in extracts libraries as well as determine relative IC50 of inhibitors.


Subject(s)
Catechol O-Methyltransferase , Monoamine Oxidase , Antiparkinson Agents , Catechol O-Methyltransferase Inhibitors/pharmacology , Catechols/chemistry , Dopa Decarboxylase , Enzyme Assays , Levodopa/therapeutic use , Mass Spectrometry , Monoamine Oxidase Inhibitors/pharmacology
3.
J Med Chem ; 59(13): 6169-86, 2016 07 14.
Article in English | MEDLINE | ID: mdl-27341519

ABSTRACT

Parkinson's disease (PD) is a neurodegenerative disorder of aging characterized by motor symptoms that result from the loss of midbrain dopamine neurons and the disruption of dopamine-mediated neurotransmission. There is currently no curative treatment for this disorder. To discover druggable neuroprotective compounds for dopamine neurons, we have designed and synthesized a second-generation of quinoxaline-derived molecules based on structure-activity relationship studies, which led previously to the discovery of our first neuroprotective brain penetrant hit compound MPAQ (5c). Neuroprotection assessment in PD cellular models of our newly synthesized quinoxaline-derived compounds has led to the selection of a better hit compound, PAQ (4c). Extensive in vitro characterization of 4c showed that its neuroprotective action is partially attributable to the activation of reticulum endoplasmic ryanodine receptor channels. Most interestingly, 4c was able to attenuate neurodegeneration in a mouse model of PD, making this compound an interesting drug candidate for the treatment of this disorder.


Subject(s)
Dopaminergic Neurons/drug effects , Neuroprotective Agents/chemistry , Neuroprotective Agents/therapeutic use , Parkinson Disease/drug therapy , Quinoxalines/chemistry , Quinoxalines/therapeutic use , Animals , Cells, Cultured , Disease Models, Animal , Dopaminergic Neurons/pathology , Female , Male , Mice, Inbred C57BL , Neuroprotective Agents/pharmacology , Parkinson Disease/pathology , Quinoxalines/pharmacology , Rats, Sprague-Dawley , Structure-Activity Relationship
4.
Chemistry ; 19(43): 14515-20, 2013 Oct 18.
Article in English | MEDLINE | ID: mdl-24030925

ABSTRACT

Mixtures of tryptamine and reactive C5 units, presumably derived from lysine in nature, were studied to ascertain the spontaneous formation of the complex polycyclic alkaloid nitrarine. Several indolic compounds tracing the unified metabolism within the Nitraria genus were also characterized.


Subject(s)
Indole Alkaloids/chemistry , Quinolizidines/chemistry , Sapindaceae/chemistry , Indole Alkaloids/chemical synthesis , Indole Alkaloids/metabolism , Oxidation-Reduction , Quinolizidines/chemical synthesis , Sapindaceae/metabolism , Tryptamines/chemistry
5.
Anal Chem ; 84(7): 3324-9, 2012 Apr 03.
Article in English | MEDLINE | ID: mdl-22409647

ABSTRACT

Drug screening for antimalarials uses heme biocrystallization inhibition methods as an alternative to parasite cultures, but they involve complex processes and cannot detect artemisinin-like molecules. The described method detects heme-binding compounds by mass spectrometry, using dissociation of the drug-heme adducts to evaluate putative antiplasmodial activity. Applied to a chemical library, it showed a good hit-to-lead ratio and is an efficient early stage screening for complex mixtures like natural extracts.


Subject(s)
Antimalarials/analysis , Antimalarials/pharmacology , Drug Discovery/methods , Heme/chemistry , Mass Spectrometry/methods , Antimalarials/chemistry , Artemisinins/analysis , Artemisinins/chemistry , Artemisinins/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...